Rosuvastatin: No Significant Benefit for Older Patients with Systolic Heart Failure: CORONA Study Results

Rosuvastatin: No Significant Benefit for Older Patients with Systolic Heart Failure: CORONA Study Results

0:00
6 November 2007

Ake Hjalmarson Gordon Tomaselli REFERENCE: Late Breaking Clinical Trials, Session 2, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida N Engl J Med 2007;357 AKE HJAL

Ake Hjalmarson

Ake Hjalmarson

Gordon Tomaselli

Gordon Tomaselli

REFERENCE: Late Breaking Clinical Trials, Session 2, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, FloridaN Engl J Med 2007;357AKE HJALMARSON, Sahlgrenska University, GöteborgCOMMENT: GORDON TOMASELLI, Johns Hopkins University, BaltimoreThe lipid lowering agent rosuvastatin did not bring a significant benefit to older patients with systolic heart failure, according to the findings of the CORONA study released at the American Heart Association sessions in Orlando.Ake Hjalmarsontalked with Peter Goodwin about the implications this has for using statins in older patients with heart failure.